Screening TRPV1 antagonists for the treatment of pain: Lessons learned over a decade

Expert Opinion on Drug Discovery

Volumn 4, Issue 2, 2009, Pages 159-180

  Lázár, József ^a   Gharat, Laxmikant ^b   Khairathkar Joshi, Neelima ^b   Blumberg, Peter M ^a   Szallasi, Arpad ^c  

^a NATIONAL CANCER INSTITUTE   (United States)

^b Glenmark Pharmaceuticals Limited   (India)

^c MONMOUTH MEDICAL CENTER   (United States)

Author keywords

Pain; TRPV1

Indexed keywords

(5 TERT BUTYL 2,3 DIHYDRO 1H INDEN 1 YL) 3 (1H INDAZOL 4 YL)UREA; 1 (2 BROMOPHENYL) 3 [1 (5 TRIFLUOROMETHYL 2 PYRIDINYL) 3 PYRROLIDINYL]UREA; 1 (4 TRIFLUOROMETHYLBENZYL) 3 (ISOQUINOL 5 YL) UREA; 2 (4 PYRIDIN 2 YLPIPERAZIN 1 YL) 1H BENZO[D]IMIDAZOLE; 3 (4 TERT BUTYLPHENYL) N (2,3 DIHYDROBENZO[B][1,4] DIOXIN 6 YL)ACRYLAMIDE; 4 (3 TRIFLUOROMETHYLPYRIDIN 2 YL) 1 (5 TRIFLUOROMETHYLPYRIDIN 2 YL)PIPERAZINE 1 CARBOXAMIDE; 4 CHLORO N (3 METHOXYPHENYL)CINNAMAMIDE; A 425619; ABT 102; AMG 2674; AMG 517; AMG 628; AMG 8562; AMG 9810; AMG 986; ANTINOCICEPTIVE AGENT; AZD 1386; CANNABINOID 1 RECEPTOR; CAPSAICIN; CAPSAZEPINE; CYCLIC AMP DEPENDENT PROTEIN KINASE; GRC 6211; JNJ 17203212; JYL 1421; LJO 328; N (2 HYDROXY 2,3 DIHYDRO 1H INDEN 4 YL) 3 [2 (PIPERIDIN 1 YL) 4 (TRIFLUOROMETHYL)PHENYL]ACRYLAMIDE; N (4 TERT BUTYLBENZYL) N' [1 [3 FLUORO 4 (METHYLSULFONYLAMINO)PHENYL]ETHYL]THIOUREA; N (4 TERT BUTYLBENZYL) N' [3 FLUORO 4 (METHYLSULFONYLAMINO)BENZYL]THIOUREA; N (4 TERT BUTYLBENZYL) N' [4 (METHYLSULFONYLAMINO)BENZYL]THIOUREA; N [4 [6 (4 TRIFLUOROMETHYLPHENYL)PYRIMIDIN 4 YLOXY]BENZOTHIAZOL 2 YL]ACETAMIDE; NGD 8243; NONSTEROID ANTIINFLAMMATORY AGENT; PHOSPHOLIPASE A2; SB 452533; TRANSIENT RECEPTOR POTENTIAL CHANNEL M; UNCLASSIFIED DRUG; UNINDEXED DRUG; VANILLOID RECEPTOR 1; VANILLOID RECEPTOR 1 BLOCKING AGENT; VANILLOID RECEPTOR 4;

ANTINOCICEPTION; CHRONIC PAIN; CLINICAL TRIAL; DRUG RESEARCH; DRUG SCREENING; DRUG STRUCTURE; FEVER; HISTORY OF MEDICINE; HUMAN; MIGRAINE; NEUROMODULATION; NEUROPATHIC PAIN; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; RECEPTOR SENSITIVITY; REVIEW;

EID: 67649206465     PISSN: 17460441     EISSN: None     Source Type: Journal    
DOI: 10.1517/17460440802681300     Document Type: Review

References (135)

1. Campbell W, Nicholas M, Breivik H, et al. Clinical Pain Management Practice and Procedures. Oxford University Press, 2008
2. Decade of Pain Control and Research Available from: http://www.ampainsoc. org/decadeofpain [Cited 2008 ]
3. Cortright DN, Szallasi A. TRP channels and pain. Curr Pharm Des 2008; In press
4. Szallasi A, Blumberg PM. Vanilloid (Capsaicin) receptors and mechanisms. Pharmacol Rev 1999;51:159-212
5. Knotkova H, Pappagallo M, Szallasi A. Capsaicin (TRPV1 agonist) therapy for pain relief - Farewell or revival? Clin J Pain 2008;24:142-154
6. Caterina MJ, Schumacher MA, Tominaga M, et al. The capsaicin receptor: a heat-activated ion channel in the pain pathway. Nature 1997;389:816-824 (Pubitemid 27462969)
7. Szallasi A, Cortright DN, Blum CA, Eid SR. The vanilloid receptor TRPV1: 10 years from channel cloning to antagonist proof-of-concept. Nat Rev Drug Discov 2007;6:357-372 (Pubitemid 46705200)
8. Migraine trials with SB-705498. Available from: http://clinicaltrials. gov/ct2/show/NCT00269022?term=SB705498&rank=1 [Cited 2008]
9. Merck "pipeline" Available from: http://www.merck.com/finance/ pipeline.swf [Cited 2008]
10. Gavva NR, Treanor JJS, Garami A, et al. Pharmacological blockade of the vanilloid receptor TRPV1 elicits marked hyperthermia in humans. Pain 2008;136:202-210
11. Hayes P, Meadows HJ, Gunthorpe MJ, et al. Cloning and functional expression of a human orthologue of rat vanilloid receptor-1. Pain 2000;88:205-215 (Pubitemid 30782628)
12. Moiseenkova-Bell VY, Stanciu LA, Serysheva II, et al. Structure of TRPV1 channel revealed by electron cryomicroscopy. Proc Natl Acad Sci USA 2008;105:7451-7455 (Pubitemid 351830038)
13. Garcia-Sanz N, Fernandez-Carvajal A, Morenilla-Palao C, et al. Identification of a tetramerization domain in the C terminus of the vanilloid receptor. J Neurosci 2004;24:5307-5314 (Pubitemid 38747671)
14. Garcia-Sanz N, Valente P, Gomis A, et al. A role of the transient receptor potential domain of vanilloid receptor I in channel gating. J Neurosci 2007;27:11641-11650 (Pubitemid 350006893)
15. Latorre R, Brauchi S, Orta G, et al. Thermo TRP channels as modular proteins with allosteric gating. Cell Calcium 2007;42:427-438 (Pubitemid 47264003)
16. Gavva NR, Klionsky L, Qu YS, et al. Molecular determinants of vanilloid sensitivity in TRPV1. J Biol Chem 2004;279:20283-20295 (Pubitemid 38623474)
17. Tousova K, Vyklicky L, Susankova K, et al. Gadolinium activates and sensitizes the vanilloid receptor TRPV1 through the external protonation sites. Mol Cell Neurosci 2005;30:207-217 (Pubitemid 41319675)
18. Brauchi S, Orta G, Salazar M, et al. A hot-sensing cold receptor: C-terminal domain determines thermosensation in transient receptor potential channels. J Neurosci 2006;26:4835-4840 (Pubitemid 44315324)
19. Xu HX, Blair NT, Clapham DE. Camphor activates and strongly desensitizes the transient receptor potential vanilloid subtype 1 channel in a vanilloid-independent mechanism. J Neurosci 2005;25:8924-8937 (Pubitemid 41384461)
20. Siemens J, Zhou S, Piskorowski R, et al. Spider toxins activate the capsaicin receptor to produce inflammatory pain. Nature 2006;444:208-212 (Pubitemid 44722061)
21. Starowicz K, Nigam S, Di Marzo V. Biochemistry and pharmacology of endovanilloids. Pharmacol Ther 2007;114:13-33
22. Klionsky L, Tamir R, Holzinger B, et al. A polyclonal antibody to the prepore loop of transient receptor potential vanilloid type 1 blocks channel activation. J Pharmacol Exp Ther 2006;319:192-198 (Pubitemid 44455123)
23. Ohta T, Imagawa T, Ito S. Novel gating and sensitizing mechanism of capsaicin receptor (TRPV1) - Tonic inhibitory regulation of extracellular sodium through the external protonation sites on TRPV1. J Biol Chem 2008;283:9377-9387
24. Guo A, Vulchanova L, Wang J, et al. Immunocytochemical localization of the vanilloid receptor 1 (VR1): relationship to neuropeptides, the P2X(3) purinoceptor and IB4 binding sites. Eur J Neurosci 1999;11:946-958
25. Cortright DN, Szallasi A. Biochemical pharmacology of the vanilloid receptor TRPV1. An update. Eur J Biochem 2004;271:1814-1819 (Pubitemid 38657335)
26. Stein AT, Ufret-Vincenty CA, Hua L, et al. Phosphoinositide 3-kinase binds to TRPV1 and mediates NGF-stimulated TRPV1 trafficking to the plasma membrane. J Gen Physiol 2006;128:509-522 (Pubitemid 44664629)
27. Zhang XM, Huang JH, McNaughton PA. NGF rapidly increases membrane expression of TRPV1 heat-gated ion channels. EMBO J 2005;24:4211-4223 (Pubitemid 41828897)
28. Hwang SW, Oh U. Hot channels in airways: pharmacology of the vanilloid receptor. Curr Opin Pharmacol 2002;2:235-242 (Pubitemid 34594361)
29. Cesare P, Dekker LV, Sardini A, et al. Specific involvement of PKC-epsilon in sensitization of the neuronal response to painful heat. Neuron 1999;23:617-624 (Pubitemid 29359931)
30. Schnizler K, Shutov LP, Van Kanegan MJ, et al. Protein kinase A anchoring via AKAP150 is essential for TRPV1 modulation by forskolin and prostaglandin E2 in mouse sensory neurons. J Neurosci 2008;28:4904-4917
31. Zhang X, Li L, McNaughton PA. Proinflammatory mediators modulate the heat-activated ion channel TRPV1 via the scaffolding protein AKAP79/150. Neuron 2008;59:450-461
32. Jeske NA, Diogenes A, Ruparel NB, et al. A-kinase anchoring protein mediates TRPV1 thermal hyperalgesia through PKA phosphorylation of TRPV1. Pain 2008 [Epub ahead of print]
33. Coghlan VM, Perrino BA, Howard M, et al. Association of protein-kinase-a and protein-phosphatase-2b with a common anchoring rotein. Science 1995;267:108-111
34. Klauck TM, Faux MC, Labudda K, et al. Coordination of three signaling enzymes by AKAP79, a mammalian scaffold protein. Science 1996;271:1589-1592 (Pubitemid 26097218)
35. Amadesi S, Cottrell GS, Divino L, et al. Protease-activated receptor 2 sensitizes TRPV1 by protein kinase C epsilon- and A-dependent mechanisms in rats and mice. J Physiol 2006;575:555-571 (Pubitemid 44270181)
36. Ohta T, Ikemi Y, Murakami M, et al. Potentiation of transient receptor potential V1 functions by the activation of metabotropic 5-HT receptors in rat primary sensory neurons. J Physiol 2006;576:809-822 (Pubitemid 44637885)
37. Kim BM, Lee SH, Shim WS, Oh U. Histamine-induced Ca2+ influx via the PLA(2)/lipoxygenase/TRPV1 pathway in rat sensory neurons. Neurosci Lett 2004;361:159-162
38. Chuang HH, Prescott ED, Kong H, et al. Bradykinin and nerve growth factor release the capsaicin receptor from PtdIns(4,5) P2-mediated inhibition. Nature 2001;411:957-962
39. Prescott ED, Julius D. A modular PIP2 binding site as a determinant of capsaicin receptor sensitivity. Science 2003;300:1284-1288 (Pubitemid 36618238)
40. Lukacs V, Thyagarajan B, Varnai P, et al. Dual regulation of TRPV1 by phosphoinositides. J Neurosci 2007;27:7070-7080 (Pubitemid 47015892)
41. Kim AY, Tang ZX, Liu Q, et al. Pirt, a phosphoinositide-binding protein, functions as a regulatory subunit of TRPV1. Cell 2008;133:475-485 (Pubitemid 351608697)
42. Premkumar LS, Ahern GP. Induction of vanilloid receptor channel activity by protein kinase C. Nature 2000;408:985-990 (Pubitemid 32101646)
43. Vellani V, Mapplebeck S, Moriondo A, et al. Protein kinase C activation potentiates gating of the vanilloid receptor VR1 by capsaicin, protons, heat and anandamide. J Physiol 2001;534:813-825 (Pubitemid 32700878)
44. Bhave G, Hu HJ, Glauner KS, et al. Protein kinase C phosphorylation sensitizes but does not activate the capsaicin receptor transient receptor potential vanilloid 1 (TRPV1). Proc Natl Acad Sci USA 2003;100:12480-12485 (Pubitemid 37271585)
45. Numazaki M, Tominaga T, Toyooka H, Tominaga M. Direct phosphorylation of capsaicin receptor VR1 by protein kinase Cepsilon and identification of two target serine residues. J Biol Chem 2002;277:13375-13378 (Pubitemid 34967929)
46. Morenilla-Palao C, Planells-Cases R, Garcia-Sanz N, Ferrer-Montiel A. Regulated exocytosis contributes to protein kinase C potentiation of vanilloid receptor activity. J Biol Chem 2004;279:25665-25672 (Pubitemid 38756829)
47. Constantin CE, Mair N, Sailer CA, et al. Endogenous tumor necrosis factor alpha (TNFalpha) requires TNF receptor type 2 to generate heat hyperalgesia in a mouse cancer model. J Neurosci 2008;28:5072-5081
48. Sculptoreanu A, Aura Kullmann F, de Groat WC. Neurokinin 2 receptor-mediated activation of protein kinase C modulates capsaicin responses in DRG neurons from adult rats. Eur J Neurosci 2008;27:3171-3181 (Pubitemid 351863592)
49. Wang Y, Kedei N, Wang M, et al. Interaction between protein kinase C mu and the vanilloid receptor type 1. J Biol Chem 2004;279:53674-53682 (Pubitemid 40051875)
50. Vetter I, Wyse BD, Monteith GR, et al. The mu opioid agonist morphine modulates potentiation of capsaicin-evoked TRPV1 responses through a cyclic AMP-dependent protein kinase A pathway. Mol Pain 2006;2:22-29 (Pubitemid 44308920)
51. Jung JY, Shin JS, Lee SY, et al. Phosphorylation of vanilloid receptor 1 by Ca2+/calmodulin-dependent kinase II regulates its vanilloid binding. J Biol Chem 2004;279:7048-7054 (Pubitemid 38248850)
52. Mohapatra DP, Nau C. Regulation of Ca2+-dependent desensitization in the vanilloid receptor TRPV1 by calcineurin and cAMP-dependent protein kinase. J Biol Chem 2005;280:13424-13432 (Pubitemid 40517230)
53. Planells-Cases R, Ferrer-Montiel AV. TRP channel trafficking. In: Liedtke WB, editor, TRP Ion Channel Function in Sensory Transduction and Cellular Signaling Cascades: CRC Press 2006. p. 467
54. Jordt SE, Julius D. Molecular basis for species-specific sensitivity to "hot" chili peppers. Cell 2002;108:421-430
55. McIntyre P, McLatchie LM, Chambers A, et al. Pharmacological differences between the human and rat vanilloid receptor 1 (VR1). Brit J Pharmacol 2001;132:1084-1094 (Pubitemid 32238914)
56. Savidge J, Davis C, Shah K, et al. Cloning and functional characterization of the guinea pig vanilloid receptor 1. Neuropharmacol 2002;43:450-456 (Pubitemid 35257937)
57. Lehto SG, Tamir R, Deng H, et al. Antihyperalgesic effects of (R,E)-N-(2-hydroxy-2,3-dihydro-1H-inden-4-yl)-3-(2-(piperidin-1-yl)-4-(tri fluoromethyl)phenyl)-acrylamide (AMG8562), a novel transient receptor potential vanilloid type 1 modulator that does not cause hyperthermia in rats. J Pharmacol Exp Ther 2008;326:218-229 (Pubitemid 351872146)
58. Szolcsanyi J, Szallasi A, Szallasi Z, et al. Resiniferatoxin - an ultrapotent selective modulator of capsaicin-sensitive primary afferent neurons. J Pharmacol Exp Ther 1990;255:923-928
59. Szallasi A, Nilsson S, Farkas-Szallasi T, et al. Vanilloid (capsaicin) receptors in the rat: distribution in the brain, regional differences in the spinal cord, axonal transport to the periphery, and depletion by systemic vanilloid treatment. Brain Res 1995;703:175-183
60. Diatchenko L, Slade GD, Nackley AG, et al. Genetic basis for individual variations in pain perception and the development of a chronic pain condition. Hum Mol Gen 2005;14:135-143 (Pubitemid 40123469)
61. Sery O, Hrazdilova O, Matalova E, Sevcik P. Pain research update from a genetic point of view. Pain Pract 2005;5:341-348 (Pubitemid 41807083)
62. Lotsch J, Geisslinger G. Are mu-opioid receptor polymorphisms important for clinical opioid therapy? Trends Mol Med 2005;11:82-89
63. Kim H, Dionne RA. TRP polymorphism: implications for theranostics. In: Szallasi A, editor, TRP Channels in Health and Disease: Implications for Diagnosis and Therapy: Nova Publ.; In press
64. Kim H, Mittal DP, Iadarola MJ, Dionne RA. Genetic predictors for acute experimental cold and heat pain sensitivity in humans. J Med Genet 2006;43:e40
65. Goldberg YP, MacFarlane J, MacDonald ML, et al. Loss-of-function mutations in the Na(v)1.7 gene underlie congenital indifference to pain in multiple human populations. Clin Genet 2007;71:311-319
66. Oertel B, Lotsch J. Genetic mutations that prevent pain: implications for future pain medication. Pharmacogenomics 2008;9:179-194 (Pubitemid 351566942)
67. Xu H, Tian W, Fu Y, et al. Functional effects of nonsynonymous polymorphisms in the human TRPV1 gene. Am J Physiol Renal Physiol 2007;293:F1865-76 (Pubitemid 350179611)
68. Kim H, Neubert JK, San Miguel A, et al. Genetic influence on variability in human acute experimental pain sensitivity associated with gender, ethnicity and psychological temperament. Pain 2004;109:488-496 (Pubitemid 38638726)
69. Razavi R, Chan Y, Afifiyan FN, et al. TRPV1(+) sensory neurons control beta cell stress and islet inflammation in autoimmune diabetes. Cell 2006;127:1123-1135 (Pubitemid 44894522)
70. Gharat LA, Szallasi A. Advances in the design and therapeutic use of capsaicin receptor TRPV1 agonists and antagonists. Exp Opin Ther Patents 2008;18:159-209
71. Walpole CSJ, Bevan S, Bovermann G, et al. The discovery of capsazepine, the first competitive antagonist of the sensory neuron excitants capsaicin and resiniferatoxin. J Med Chem 1994;37:1942-1954 (Pubitemid 24233606)
72. Bevan S, Hothi S, Hughes G, et al. Capsazepine - a competitive antagonist of the sensory neuron excitant capsaicin. Br J Pharmacol 1992;107:544-552
73. Szallasi A, Goso C, Blumberg PM, Manzini S. Competitive-inhibition by capsazepine of [H-3] resiniferatoxin binding to central (spinal-cord and dorsal-root ganglia) and peripheral (urinary-bladder and airways) vanilloid (capsaicin) receptors in the rat. J Pharmacol Exp Ther 1993;267:728-733 (Pubitemid 23352531)
74. Correll CC, Phelps PT, Anthes JC, et al. Cloning and pharmacological characterization of mouse TRPV1. Neurosci Lett 2004;370:55-60 (Pubitemid 39369856)
75. Walker KM, Urban L, Medhurst SJ, et al. The VR1 antagonist capsazepine reverses mechanical hyperalgesia in models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 2003;304:56-62 (Pubitemid 36008912)
76. Behrendt HJ, Germann T, Gillen C, et al. Characterization of the mouse cold-menthol receptor TRPM8 and vanilloid receptor type-1 VR1 using a fluorometric imaging plate reader (FLIPR) assay. Br J Pharmacol 2004;141:737-745 (Pubitemid 38453266)
77. Seabrook GR, Sutton KG, Jarolimek W, et al. Functional properties of the high-affinity TRPV1 (VR1) vanilloid receptor antagonist (4-hydroxy-5-iodo-3- methoxyphenyl acetate ester) iodo-resiniferatoxin. J Pharmacol Exp Ther 2002;303:1052-1060 (Pubitemid 35424389)
78. Shimizu I, Iida T, Horiuchi N, Caterina MJ. 5-Iodoresiniferatoxin evokes hypothermia in mice and is a partial transient receptor potential vanilloid 1 agonist in vitro. J Pharmacol Exp Ther 2005;314:1378-1385 (Pubitemid 41206005)
79. Wahl P, Foged C, Tullin S, Thomsen C. Iodo-resiniferatoxin, a new potent vanilloid receptor antagonist. Mol Pharmacol 2001;59:9-15
80. Lazar J, Braun DC, Toth A, et al. Kinetics of penetration influence the apparent potency of vanilloids on TRPV1. Mol Pharmacol 2006;69:1166-1173
81. Kanai Y, Hara T, Imai A. Participation of the spinal TRPV1 receptors in formalin-evoked pain transduction: a study using a selective TRPV1 antagonist, iodo-resiniferatoxin. J Pharm Pharmacol 2006;58:489-493
82. Appendino G, Harrison S, De Petrocellis L, et al. Halogenation of a capsaicin analogue leads to novel vanilloid TRPV1 receptor antagonists. Brit J Pharmacol 2003;139:1417-1424 (Pubitemid 37174655)
83. Appendino G, Daddario N, Minassi A, et al. The taming of capsaicin. Reversal of the vanilloid activity of N-acylvanillamines by aromatic iodination. J Med Chem 2005;48:4663-4669 (Pubitemid 40993425)
84. Wang Y, Szabo T, Welter JD, et al. High affinity antagonists of the vanilloid receptor. Mol Pharmacol 2002;62:947-956
85. Jakab B, Helyes Z, Varga A, et al. Pharmacological characterization of the TRPV1 receptor antagonist JYL1421 (SC0030) in vitro and in vivo in the rat. Eur J Pharmacol 2005;517:35-44 (Pubitemid 40910250)
86. Miranda A, Nordstrom E, Mannem A, et al. The role of transient receptor potential vanilloid 1 in mechanical and chemical visceral hyperalgesia following experimental colitis. Neuroscience 2007;148:1021-1032 (Pubitemid 47419190)
87. Thomas KC, Sabnis AS, Johansen ME, et al. Transient receptor potential vanilloid 1 agonists cause endoplasmic reticulum stress and cell death in human lung cells. J Pharmacol Exp Ther 2007;322:830-838 (Pubitemid 46762717)
88. Toth A, Blumberg PM, Chen Z, Kozikowski AP. Design of a high-affinity competitive antagonist of the vanilloid receptor selective for the calcium entry-linked receptor population. Mol Pharmacol 2004;65:282-291 (Pubitemid 38134255)
89. Tang L, Chen Y, Chen ZL, et al. Antinociceptive pharmacology of N-(4-chlorobenzyl)-N′-(4-hydroxy-3-iodo-5-methoxybenzyl) thiourea, a high-affinity competitive antagonist of the transient receptor potential vanilloid 1 receptor. J Pharmacol Exp Ther 2007;321:791-798 (Pubitemid 46624524)
90. Gunthorpe MJ, Rami HK, Jerman JC, et al. Identification and characterisation of SB-366791, a potent and selective vanilloid receptor (VR1/TRPV1) antagonist. Neuropharmacol 2004;46:133-149 (Pubitemid 37494747)
91. Gavva NR, Tamir R, Qu YS, et al. AMG 9810 [(E)-3-(4-t-butylphenyl)-N-(2, 3-dihydrobenzo[b][1,4]dioxin-6-yl) acrylamide], a novel vanilloid receptor 1 (TRPV1) antagonist with antihyperalgesic properties. J Pharmacol Exp Ther 2005;313:474-484
92. Gavva NR. Body-temperature maintenance as the predominant function of the vanilloid receptor TRPV1. Trends Pharmacol Sci 2008;19:19-23
93. Sun Q, Tafesse L, Islam K, et al. 4-(2-Pyridyl)piperazine-1-carboxamides: potent vanilloid receptor 1 antagonists. Bioorg Med Chem Lett 2003;13:3611-3616 (Pubitemid 37150471)
94. Pomonis JD, Harrison JE, Mark L, et al. N-(4-tertiarybutylphenyl)-4-(3- cholorphyridin-2-yl) tetrahydropyrazine-1(2H)-carbox-amide(BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: II. In vivo characterization in rat models of inflammatory and neuropathic pain. J Pharmacol Exp Ther 2003;306:387-393
95. Takeda Y, Ishida T, Tsutsui R, et al. Studies on somnolence in the daytime caused by drugs used for neuropathic pain. J Pharmacol Sci 2008;107:246-250 (Pubitemid 352030310)
96. Tafesse L, Sun Q, Schmid L, et al. Synthesis and evaluation of pyridazinylpiperazines as vanilloid receptor 1 antagonists. Bioorg Med Chem Lett 2004;14:5513-5519 (Pubitemid 39346336)
97. Swanson DM, Dubin AE, Shah C, et al. Identification and biological evaluation of 4-(3-trifluoromethylpyridin-2-yl) piperazine-1-carboxylic acid (5-trifluoromethylpyridin-2-yl)amide, a high affinity TRPV1 (VR1) vanilloid receptor antagonist. J Med Chem 2005;48:1857-1872 (Pubitemid 40396317)
98. Bhattacharya A, Scott BP, Nasser N, et al. Pharmacology and antitussive efficacy of 4-(3-trifluoromethylpyridin2-yl)-piperazine-1-carboxylic acid (5-trifluoromethylpyridin2-yl)-amide (JNJ17203212), a transient receptor potential vanilloid 1 antagonist in guinea pigs. J Pharmacol Exp Ther 2007;323:665-674 (Pubitemid 350005126)
99. Ognyanov VI, Balan C, Bannon AW, et al. Design of potent, orally available antagonists of the transient receptor potential vanilloid 1. Structure-activity relationships of 2-piperazin-1-yl-1H-benzimidazoles. J Med Chem 2006;49:3719-3742 (Pubitemid 43902478)
100. Zheng XZ, Hodgetts KJ, Brielmann H, et al. From arylureas to biarylamides to aminoquinazolines: Discovery of a novel, potent TRPV1 antagonist. Bioorg Med Chem Lett 2006;16:5217-5221 (Pubitemid 44247688)
101. Blum CA, Zheng X, Brielmann H, et al. Aminoquinazolines as TRPV1 antagonists: modulation of drug-like properties through the exploration of 2-position substitution. Bioorg Med Chem Lett 2008;18:4573-4577
102. Jetter MC, Youngman MA, McNally JJ, et al. N-Isoquinolin-5-yl-N′- aralkyl-urea and -amide antagonists of human vanilloid receptor 1. Bioorg Med Chem Lett 2004;14:3053-3056 (Pubitemid 38624561)
103. Gomtsyan A, Bayburt EK, Schmidt RG, et al. Novel transient receptor potential vanilloid 1 receptor antagonists for the treatment of pain: Structure-activity relationships for ureas with quinoline, isoquinoline, quinazoline, phthalazine, quinoxaline, and cinnoline moieties. J Med Chem 2005;48:744-752 (Pubitemid 40209096)
104. El Kouhen R, Surowy CS, Bianchi BR, et al. A-425619 [1-isoquinolin-5-yl- 3-(4-trifluoromethyl-benzyl)-urea], a novel and selective transient receptor potential type V1 receptor antagonist, blocks channel activation by vanilloids, heat, and acid. J Pharmacol Exp Ther 2005;314:400-409 (Pubitemid 41058278)
105. Honore P, Wismer CT, Mikusa J, et al. A-425619 [1-isoquinolin-5-yl-3-(4- trifluoromethyl-benzyl)-urea], a novel transient receptor potential type V1 receptor antagonist, relieves pathophysiological pain associated with inflammation and tissue injury in rats. J Pharmacol Exp Ther 2005;314:410-421 (Pubitemid 41058279)
106. Rami HK, Thompson M, Wyman P, et al. Discovery of small molecule antagonists of TRPV1. Bioorg Med Chem Lett 2004;14:3631-3634 (Pubitemid 38760052)
107. Rami HK, Thompson M, Stemp G, et al. Discovery of SB-705498: A potent, selective and orally bioavailable TRPV1 antagonist suitable for clinical development. Bioorg Med Chem Lett 2006;16:3287-3291 (Pubitemid 43732339)
108. Gomtsyan A, Bayburt EK, Schmidt RG, et al. Discovery of TRPV1 antagonist ABT-102 for treatment of pain. 236th National ACS meeting. Philadelphia, PA; 2008:131
109. Surowy CS, Neelands TR, Bianchi BR, et al. (R)-(5-tert-butyl-2,3-dihydro- 1H-inden-1-yl)-3-(1H-indazol-4-yl)-urea (ABT-102) blocks polymodal activation of transient receptor potential vanilloid 1 receptors in vitro and heat-evoked firing of spinal dorsal horn neurons in vivo. J Pharmacol Exp Ther 2008;326:879-888
110. Doherty EM, Fotsch C, Bo YX, et al. Discovery of potent, orally available vanilloid receptor-1 antagonists. Structure-activity relationship of N-aryl cinnamides. J Med Chem 2005;48:71-90 (Pubitemid 40105250)
111. Norman MH, Zhu JW, Fotsch C, et al. Novel vanilloid receptor-1 antagonists: 1. Conformationally restricted analogues of trans-cinnamides. J Med Chem 2007;50:3497-3514
112. Gavva NR, Bannon AW, Hovland DN, et al. Repeated administration of vanilloid receptor TRPV1 antagonists attenuates hyperthermia elicited by TRPV1 blockade. J Pharmacol Exp Ther 2007;323: 128-137 (Pubitemid 47443270)
113. Tamayo N, Liao HY, Stec MM, et al. Design and synthesis of peripherally restricted transient receptor potential vanilloid 1 (TRPV1) antagonists. J Medi Chem 2008;51:2744-2757 (Pubitemid 351620796)
114. Press release: osteoarthritis trials with GRC 6211 are suspended. Available from: http://www.glenmarkpharma.com/media/pdf/releases/GRC-6211.pdf [Cited 2008]
115. Patapoutian A, Tate S, Woolf CJ. TRP channels: targeting pain at the source. Nat Rev Drug Discov; In press
116. McMahon SB, Wood JN. Increasingly irritable and close to tears: TRPA1 in inflammatory pain. Cell 2006;124:1123-1125
117. Fiorentino PM, Tallents RH, Miller JN, et al. Spinal interleukin-1beta in a mouse model of arthritis and joint pain. Arthritis Rheum 2008;58:3100-3109
118. Liu L, Yang TM, Liedtke W, Simon SA. Chronic IL-1beta signaling potentiates voltage-dependent sodium currents in trigeminal nociceptive neurons. J Neurophysiol 2006;95:1478-1490
119. Cruwys SC, Garrett NE, Kidd BC. Sensory denervation with capsaicin attenuates inflammation and nocicpetion in arthritic rats. Neurosci Lett 1995;193:205-207
120. Honore P. TRPV1 and osteoarthritis pain. In: Feltynek C, Gomtsyan A, editors, Vanilloid Receptor TRPV1 in Drug Discovery: Targeting Pain and other Pathological Disorders, John Wiley; In press
121. Raffa RB. Mechanism of action of analgesics used to treat osteoarthritis pain. Rheum Dis Clin North Am 2003;29:733-745 (Pubitemid 37296768)
122. Anesiva announces Adlea ACTIVE-1 Phase-3 clinical trial results. Available from: http://investors.anesiva.com/media.cfm?Year=2008. [Cited 2008]
123. V377 by PharmEste is a potent TRPV1 antagonist for pain management. Available from: http://www.eocweb.com/pdf-docs/EOC-ENC-Abstract-book.pdf [Cited 2008]
124. Gavva NR, Bannon AW, Surapaneni S, et al. The vanilloid receptor TRPV1 is tonically activated in vivo and involved in body temperature regulation. J Neurosci 2007;27:3366-3374 (Pubitemid 46515121)
125. Chung JU, Kim SY, Lim JO, et al. alpha-Substituted N-(4-tert-butylbenzyl) -N′-[4-(methylsulfonylamino)benzyl] thiourea analogues as potent and stereospecific TRPV1 antagonists. Bioorg Med Chem 2007;15:6043-6053 (Pubitemid 47088969)
126. Gavva NR, Tamir R, Klionsky L, et al. Proton activation does not alter antagonist interaction with the capsaicin-binding pocket of TRPV1. Mol Pharmacol 2005;68:1524-1533 (Pubitemid 41654336)
127. Valenzano KJ, Grant ER, Wu G, et al. N-(4-tertiarybutylphenyl)-4-(3- chloropyridin-2-yl) tetrahydropyrazine- 1(2H)-carbox-amide(BCTC), a novel, orally effective vanilloid receptor 1 antagonist with analgesic properties: I. In vitro characterization and pharmacokinetic properties. J Pharmacol Exp Ther 2003;306:377-386
128. McDonald HA, Neelands TR, Kort M, et al. Characterization of A-425619 at native TRPV1 receptors: A comparison between dorsal root ganglia and trigeminal ganglia. Eur J Pharmacol 2008
129. Doherty EM, Fotsch C, Bannon AW, et al. Novel vanilloid receptor-1 antagonists: 2. Structure-activity relationships of 4-oxopyrimidines leading to the selection of a clinical candidate. J Med Chem 2007;50:3515-3527
130. Wang HL, Katon J, Balan C, et al. Novel vanilloid receptor-1 antagonists:3. The identification of a second-generation clinical candidate with improved physicochemical and pharmacokinetic properties. J Med Chem 2007;50:3528-3539
131. Gunthorpe MJ, Hannan SL, Smart D, et al. Characterization of SB-705498, a potent and selective vanilloid receptor-1 (VR1/TRPV1) antagonist that inhibits the capsaicin-, acid-, and heat- mediated activation of the receptor. J Pharmacol Exp Ther 2007;321:1183-1192 (Pubitemid 46762715)
132. Rigoni M, Trevisani M, Gazzieri D, et al. Neurogenic responses mediated by vanilloid receptor-1 (TRPV1) are blocked by the high affinity antagonist, iodo-resiniferatoxin. Brit J Pharmacol 2003;138:977-985 (Pubitemid 36390655)
133. Kanai Y, Nakazato E, Fujiuchi A, et al. Involvement of an increased spinal TRPV1 sensitization through its up-regulation in mechanical allodynia of CCI rats. Neuropharmacology 2005;49:977-984 (Pubitemid 41503297)
134. McGaraughty S, Chu KL, Faltynek CR, Jarvis MF. Systemic and site-specific effects of A-425619, a selective TRPV1 receptor antagonist, on wide dynamic range neurons in CFA-treated and uninjured rats. J Neurophysiol 2006;95:18-25 (Pubitemid 44698913)
135. Chizh BA, O'Donnell MB, Napolitano A, et al. The effects of the TRPV1 antagonist SB-705498 on TRPV1 receptor-mediated activity and inflammatory hyperalgesia in humans. Pain 2007;132:132-141 (Pubitemid 47494566)